Traders Buy Merck & Company, Inc. (MRK) on Weakness
Investors purchased shares of Merck & Company, Inc. (NYSE:MRK) on weakness during trading hours on Wednesday. $188.00 million flowed into the stock on the tick-up and $102.00 million flowed out of the stock on the tick-down, for a money net flow of $86.00 million into the stock. Of all equities tracked, Merck & had the 6th highest net in-flow for the day. Merck & traded down ($0.68) for the day and closed at $63.78
Several research analysts recently issued reports on MRK shares. UBS AG increased their target price on shares of Merck & from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies set a $70.00 target price on shares of Merck & and gave the stock a “buy” rating in a research note on Saturday, July 29th. BMO Capital Markets reissued a “buy” rating and set a $74.00 target price on shares of Merck & in a research note on Tuesday, June 27th. Zacks Investment Research lowered shares of Merck & from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Finally, BidaskClub raised shares of Merck & from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Three analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $70.13.
The stock has a market capitalization of $174.09 billion, a P/E ratio of 34.56 and a beta of 0.80. The company’s 50 day moving average is $64.51 and its 200 day moving average is $63.70.
Merck & (NYSE:MRK) last announced its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.14. The company had revenue of $9.93 billion for the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. Merck &’s revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.93 EPS. Analysts expect that Merck & Company, Inc. will post $3.87 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, October 6th. Investors of record on Friday, September 15th were paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 2.95%. The ex-dividend date of this dividend was Thursday, September 14th. Merck &’s payout ratio is 76.11%.
A number of institutional investors have recently made changes to their positions in the stock. First National Bank of Mount Dora Trust Investment Services boosted its stake in Merck & by 7.1% in the 3rd quarter. First National Bank of Mount Dora Trust Investment Services now owns 79,350 shares of the company’s stock worth $5,081,000 after purchasing an additional 5,275 shares in the last quarter. Park National Corp OH boosted its stake in Merck & by 3.9% in the 3rd quarter. Park National Corp OH now owns 422,012 shares of the company’s stock worth $27,022,000 after purchasing an additional 15,898 shares in the last quarter. Cacti Asset Management LLC boosted its stake in Merck & by 5.1% in the 3rd quarter. Cacti Asset Management LLC now owns 738,840 shares of the company’s stock worth $47,308,000 after purchasing an additional 35,997 shares in the last quarter. Perpetual Ltd boosted its stake in Merck & by 3.5% in the 2nd quarter. Perpetual Ltd now owns 195,627 shares of the company’s stock worth $12,538,000 after purchasing an additional 6,650 shares in the last quarter. Finally, Bogart Wealth LLC boosted its stake in Merck & by 42.7% in the 2nd quarter. Bogart Wealth LLC now owns 23,389 shares of the company’s stock worth $1,499,000 after purchasing an additional 6,998 shares in the last quarter. Institutional investors own 72.91% of the company’s stock.
WARNING: “Traders Buy Merck & Company, Inc. (MRK) on Weakness” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/13/traders-buy-merck-company-inc-mrk-on-weakness-2.html.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.